Results(4617)
Risk of lactic acidosis with metformin use in type 2 diabetes mellitus with renal impairment: retrospective cohort study
United Kingdom
EU PAS number:
EUPAS8658
First published:
27/03/2026
Study
Finalised
A Study Assessing the U.S. Post-Marketing Safety Profile of Rebif® in comparison with its U.S. Prescribing Information
United States
EU PAS number:
EUPAS7290
First published:
27/03/2026
Study
Finalised
Centre for Maternal, Fetal and Infant Research (MFIR), Ulster University
United Kingdom (Northern Ireland)
First published:
27/03/2026
Institution
Educational Institution
ENCePP partner
The Cancer Registry of Norway
First published:
27/03/2026
Norway
Data source
Human
Cancer registry
Disease registryRecord completeness: 97%
German Pharmacoepidemiological Research Database
First published:
27/03/2026
Germany
Data source
Human
Administrative healthcare records (e.g., claims)Record completeness: 90%
Save Sight Registries
First published:
27/03/2026
Australia
Austria
Belgium
Bosnia and Herzegovina
Canada
Egypt
Fiji
France
Germany
India
Indonesia
Ireland
Italy
Japan
Jordan
Lebanon
Mexico
Nepal
Netherlands
New Zealand
Nigeria
Portugal
Serbia
Singapore
Slovakia
Slovenia
South Africa
Spain
Switzerland
Taiwan
United Arab Emirates
United Kingdom
Data source
Human
Disease registry
OtherRecord completeness: 90%
Dutch Keratinocyte Cancer Collaborative
First published:
27/03/2026
Netherlands
Data source
Human
Administrative healthcare records (e.g., claims)
Disease registry
OtherRecord completeness: 94%
Assessing Long-Term Outcomes of DUPIXENT® Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyposis (AROMA)
Canada
Germany
Italy
Japan
Netherlands
United States
EU PAS number:
EUPAS41565
First published:
27/03/2026
Study
Ongoing
Comparative Effectiveness of Osteoporosis Medications Among Female Medicare Fee-For-Service (FFS) Beneficiaries in the United States (20210028)
United States
EU PAS number:
EUPAS49101
First published:
27/03/2026
Study
Finalised
Real-World Clinical Outcomes in Patients with Severe Asthma Treated with Tezepelumab: A Retrospective Observational Study of CHRONICLE and ISAR (SYNERGY)
Belgium
Brazil
Canada
Germany
Greece
Hungary
Italy
Japan
Mexico
Netherlands
Norway
Poland
Saudi Arabia
Singapore
Spain
Switzerland
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000951
First published:
27/03/2026
Study
Ongoing
Incidence and pattern description of gastrointestinal, skin, genital, corneal, and mucosal erosions, ulcerations, perforations, haemorrhages, fistulas, abscesses, delayed wound healing and death among patients treated with nicorandil with and without diverticular disease
United Kingdom
EU PAS number:
EUPAS13205
First published:
26/03/2026
Study
Finalised
Post-Approval Observational Cohort Study to Evaluate the Safety of the COMIRNATY 2023-2024 Formula in the United States
United States
EU PAS number:
EUPAS108135
First published:
26/03/2026
Study
Ongoing
Non-Interventional Postmarketing Safety Study of the COMIRNATY 2025-2026 Formula (LP.8.1) in the United States
United States
EU PAS number:
EUPAS1000000932
First published:
26/03/2026
Study
Ongoing
A European Study of the Effectiveness of Risk Minimisation Measures for Fenfluramine in Dravet Syndrome (TAPESTRY eRMM)
Austria
Denmark
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS48741
First published:
26/03/2026
Study
Finalised
Adakveo (crizanlizumab) PRegnancy outcomes Intensive Monitoring (PRIM)
Switzerland
EU PAS number:
EUPAS39412
First published:
26/03/2026
Study
Finalised
Isotretinoin, Contraception, and Pregnancy Outcomes
Canada
EU PAS number:
EUPAS1000000927
First published:
26/03/2026
Study
Ongoing
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
United States
EU PAS number:
EUPAS45356
First published:
26/03/2026
Study
Ongoing
Safety of IL-17 and IL-23 inhibitors as treatment for immune mediated inflammatory diseases at conception and during pregnancy: an ENTIS study. (SAFE-PPREG)
Belgium
France
Germany
Ireland
Israel
Italy
Netherlands
Switzerland
United Kingdom
EU PAS number:
EUPAS1000000960
First published:
26/03/2026
Study
Ongoing
Effectiveness of mRESVIA Against Serious Endpoints related to RSV in Kaiser Permanente Northern California (ERASE-RSV)
United States
EU PAS number:
EUPAS1000000946
First published:
26/03/2026
Study
Ongoing
Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic and Natural History Study (PNHS)
First published:
25/03/2026
Belgium
France
Germany
Greece
Italy
Netherlands
Spain
Sweden
Switzerland
United Kingdom
Data source
Human
OtherRecord completeness: 82%
CureDRPLA Global Patient Registry
First published:
25/03/2026
Canada
Italy
Japan
Korea, Republic of
Netherlands
New Zealand
United Kingdom
United States
Data source
Human
Disease registry
OtherRecord completeness: 82%
Real World Use, Effectiveness and Safety of Romosozumab among Osteoporosis Patients in Guangdong China (20250009)
China
EU PAS number:
EUPAS1000000758
First published:
25/03/2026
Study
Planned
Safety and effectiveness of RZV in adults ≥18 years of age with Systemic lupus erythematosus (SLE) or Multiple sclerosis (MS) (EPI-ZOSTER-041 VS US DB 215104)
United States
EU PAS number:
EUPAS107073
First published:
25/03/2026
Study
Ongoing
MS700568_0004: Pregnancy outcomes in women exposed to oral cladribine: a multi-country cohort database study (CLEAR)
Denmark
Finland
France
Germany
Norway
Sweden
United Kingdom
EU PAS number:
EUPAS25027
First published:
25/03/2026
Study
Ongoing
MS200095_0050: Disease Registry on Patients with Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Austria
Belgium
Canada
Czechia
France
Germany
Israel
Italy
Netherlands
Portugal
Spain
Sweden
United Kingdom
United States
EU PAS number:
EUPAS47602
First published:
25/03/2026
Study
Ongoing
MS100070_0114: Avelumab in real-world treatment of urothelial cancer – The AVENUE NIS
Germany
Russian Federation
Spain
Switzerland
EU PAS number:
EUPAS42413
First published:
25/03/2026
Study
Ongoing
An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)
Belgium
Bulgaria
Croatia
France
Greece
Netherlands
Poland
Romania
Slovenia
Spain
EU PAS number:
EUPAS103632
First published:
24/03/2026
Study
Planned
Understanding drug utilisation, treatment patterns, clinical outcomes, and profile of the patients receiving lutetium (177Lu) vipivotide tetraxetan for the treatment of metastatic prostate cancer: a multicountry, AI-powered registry (PULSE)
Canada
Germany
Italy
Portugal
Switzerland
EU PAS number:
EUPAS1000000935
First published:
24/03/2026
Study
Planned
The Eplontersen Pregnancy and Lactation Outcomes Study: A Descriptive Safety Study of Pregnant and Lactating Individuals and Their Offspring Exposed to Eplontersen (EPPRO)
Argentina
Armenia
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
China
Croatia
Czechia
Denmark
Estonia
European Union
Finland
France
Georgia
Germany
Greece
Greenland
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Korea, Democratic People's Republic of
Latvia
Lithuania
Luxembourg
Netherlands
New Zealand
Norway
Other
Poland
Portugal
Romania
Singapore
South Africa
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Arab Emirates
United Kingdom
United Kingdom (Northern Ireland)
United States
EU PAS number:
EUPAS1000000736
First published:
24/03/2026
Study
Planned
EMA/2020/46/TDA, Lot 3 - ROC36 Use of causal inference methods commonly used in non-interventional studies to estimate treatment effects in clinical trials
Austria
Germany
Sweden
EU PAS number:
EUPAS1000000720
First published:
24/03/2026
Study
Ongoing
ERN eUROGEN registry
First published:
24/03/2026
Austria
Belgium
Croatia
Czechia
Denmark
Finland
France
Germany
Italy
Lithuania
Netherlands
Poland
Portugal
Spain
Sweden
Data source
Human
Congenital anomaly registry
Disease registryRecord completeness: 90%
University of Pécs Clinical Care Records Database
First published:
24/03/2026
Hungary
Data source
Human
Emergency care discharge records
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Specialist ambulatory care recordsRecord completeness: 75%
DARWIN EU® - Population demographics and disease frequency across the DARWIN EU® network
Belgium
Croatia
Estonia
France
Germany
Greece
Hungary
Netherlands
Norway
Portugal
Spain
Sweden
United Kingdom
EU PAS number:
EUPAS1000000962
First published:
24/03/2026
Study
Ongoing
Long-term effectiveness of cladribine in patients previously treated with oral cladribine: a Real-World Evidence analysis using data from the Italian Registry of Multiple Sclerosis (CLARINET-MS)
Italy
EU PAS number:
EUPAS25783
First published:
23/03/2026
Study
Finalised
id.DRIVE study of brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000035
First published:
23/03/2026
Study
Ongoing
id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS42328
First published:
23/03/2026
Study
Ongoing
id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe
France
Germany
Italy
Spain
United Kingdom
EU PAS number:
EUPAS1000000012
First published:
23/03/2026
Study
Ongoing
COHORT STUDY ON THE SAFETY OF BIMEKIZUMAB IN PATIENTS WITH PLAQUE PSORIASIS, PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR HIDRADENITIS SUPPURATIVA: A NON-INTERVENTIONAL POST AUTHORIZATION STUDY
France
United States
EU PAS number:
EUPAS1000000003
First published:
23/03/2026
Study
Ongoing
Compare data sources